<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39238427</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage.</ArticleTitle><Pagination><StartPage>e70007</StartPage><MedlinePgn>e70007</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.70007</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kajiyama</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Office of Regulatory Science Research, Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komamine</LastName><ForeName>Maki</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8390-0922</Identifier><AffiliationInfo><Affiliation>Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horiuchi</LastName><ForeName>Naoya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iguchi</LastName><ForeName>Toyotaka</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uyama</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0430-9887</Identifier><AffiliationInfo><Affiliation>Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="Y">Product Surveillance, Postmarketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017891" MajorTopicYN="N">Pharmacoepidemiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">drug safety</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">regulatory decisions</Keyword><Keyword MajorTopicYN="N">safety measures</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39238427</ArticleId><ArticleId IdType="doi">10.1002/pds.70007</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>E. Bakker, K. Plueschke, C. J. Jonker, X. Kurz, V. Starokozhko, and P. G. M. Mol, “Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making,” Clinical Pharmacology and Therapeutics 113, no. 1 (January 2023): 135–151, https://doi.org/10.1002/cpt.2766.</Citation></Reference><Reference><Citation>K. Nishioka, T. Makimura, A. Ishiguro, T. Nonaka, M. Yamaguchi, and Y. Uyama, “Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan,” Clinical Pharmacology and Therapeutics 111, no. 1 (2022): 35–43, https://doi.org/10.1002/cpt.2410.</Citation></Reference><Reference><Citation>C. A. Purpura, E. M. Garry, N. Honig, A. Case, and J. A. Rassen, “The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications,” Clinical Pharmacology and Therapeutics 111, no. 1 (2022): 135–144, https://doi.org/10.1002/cpt.2474.</Citation></Reference><Reference><Citation>J. C. Maro, M. D. Nguyen, J. Kolonoski, et al., “Six Years of the US Food and Drug Administration's Postmarket Active Risk Identification and Analysis System in the Sentinel Initiative: Implications for Real World Evidence Generation,” Clinical Pharmacology and Therapeutics 114, no. 4 (2023): 815–824, https://doi.org/10.1002/cpt.2979.</Citation></Reference><Reference><Citation>K. Plueschke, C. Jonker, V. Strassmann, and X. Kurz, “Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database,” Drug Safety 45, no. 7 (July 2022): 747–754, https://doi.org/10.1007/s40264‐022‐01188‐x.</Citation></Reference><Reference><Citation>M. Yamaguchi, S. Inomata, S. Harada, et al., “Establishment of the MID‐NET® Medical Information Database Network as a Reliable and Valuable Database for Drug Safety Assessments in Japan,” Pharmacoepidemiology and Drug Safety 28 (2019): 1395–1404, https://doi.org/10.1002/pds.4879.</Citation></Reference><Reference><Citation>K. Yamada, M. Itoh, Y. Fujimura, et al., “The Utilization and Challenges of Japan's MID‐NET® Medical Information Database Network in Post‐Marketing Drug Safety Assessments: A Summary of Pilot Pharmacoepidemiological Studies,” Pharmacoepidemiology and Drug Safety 28 (2019): 601–608, https://doi.org/10.1002/pds.4777.</Citation></Reference><Reference><Citation>H. Shida, K. Kajiyama, S. Sawada, et al., “Use of National Database of Health Insurance Claims and Specific Health Checkups for Examining Practical Utilization and Safety Signal of a Drug to Support Regulatory Assessment on Postmarketing Drug Safety in Japan,” Frontiers in Medicine 10 (February 2023): 1096992, https://doi.org/10.3389/fmed.2023.1096992.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Devices Agency, “The New System for Early Detection of Safety Signal Based on RWD From MID‐NET®,” 2024, https://www.pmda.go.jp/safety/surveillance‐analysis/0049.html.</Citation></Reference><Reference><Citation>H. Shida, M. Komamine, K. Kajiyama, T. Waki, H. Maruyama, and Y. Uyama, “Real‐World Prescription of Anti‐COVID‐19 Drugs in Hospitalized Patients With COVID‐19 in Japan,” PLoS One 19, no. 1 (2024): e0297679, https://doi.org/10.1371/journal.pone.0297679.</Citation></Reference><Reference><Citation>Y. Kinoshita, K. Kajiyama, C. Ishiguro, et al., “Characterizing Granulocytopenia Associated With Thiamazole in Patients With Hyperthyroidism Based on Real‐World Data From the MID‐NET® in Japan,” Clinical Pharmacology and Therapeutics 113, no. 4 (January 2023): 924–931, https://doi.org/10.1002/cpt.2850.</Citation></Reference><Reference><Citation>T. Waki, Y. Okada, Y. Kinoshita, et al., “Prescription Trend and Lactic Acidosis in Patients Prescribed Metformin Before and After the Revision of Package Insert for Allowing Metformin Administration to Patients With Moderately Decreased Kidney Function Based on Real‐World Data From MID‐NET® in Japan,” Frontiers in Medicine 10 (January 2024): 10, https://doi.org/10.3389/fmed.2023.1294696.</Citation></Reference><Reference><Citation>G. J. Dal Pan, “The Use of Real‐World Data to Assess the Impact of Safety‐Related Regulatory Interventions,” Clinical Pharmacology and Therapeutics 111, no. 1 (January 2022): 98–107, https://doi.org/10.1002/cpt.2464.</Citation></Reference><Reference><Citation>“Ministry of Health, Labour and Welfare, Future Direction About Linkage of the Nursing Care Insurance Database With Other Database (No. 6 of the 9th Committee Meeting Documents),” 2024, https://www.mhlw.go.jp/content/12301000/000995137.pdf.</Citation></Reference><Reference><Citation>“ICH M14 Expert Working Group, General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies That Utilize Real‐World Data for Safety Assessment of Medicines,” accessed August 12, 2022, https://www.ich.org/page/multidisciplinary‐guidelines.</Citation></Reference><Reference><Citation>“The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Reflection Paper, International Harmonisation of Real‐World Evidence Terminology and Convergence of General Principles Regarding Planning and Reporting of Studies Using Real‐World Data, With a Focus on Effectiveness of Medicines (Endorsed by the ICH Assembly on June 13, 2023),” accessed January 24, 2024, https://admin.ich.org/sites/default/files/2023‐06/ICH_ReflectionPaper_Harmonisation_RWE_Terminology_Endorsed‐ForConsultation_2023_0613.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>